BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/500/0.1/20.12.24 Stock BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/500/0.1/20.12.24
Add to a list
To use this feature you must be a member
Log inSign up

BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/500/0.1/20.12.24 Share Price

Warrant

DE000VD5VSC2

Real-time Bid/Ask 06:05:48 24/06/2024 pm IST
2.69 EUR / 2.75 EUR -2.16% Intraday chart for BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/500/0.1/20.12.24
Current month+31.13%
1 month+38.31%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart VERTEX PHARMACEUTICALS INCORPORATED
Chart BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/500/0.1/20.12.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $555 From $540 MT
Vertex Pharmaceuticals Discloses 'Positive' Data From Phase 1/2 Trial of VX-880 to Treat Type 1 Diabetes MT
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions BU
Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes CI
More news

Quotes 5-day view

Date Price Change
24/24/24 2.59 -6.83%
21/24/21 2.78 +6.51%
20/24/20 2.61 -2.61%
19/24/19 2.68 -8.84%
18/24/18 2.94 -15.52%

Delayed Quote Börse Stuttgart

Last update June 24, 2024 at 12:12 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying VERTEX PHARMACEUTICALS INCORPORATED
IssuerLogo Issuer Vontobel Vontobel
WKN VD5VSC
ISINDE000VD5VSC2
Date issued 08/05/2024
Strike 500 $
Maturity 20/12/2024 (179 Days)
Parity 10 : 1
Emission price 0.87 €
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 3.78 €
Lowest since issue 1.3 €
Delta0.46x
Omega 7.347
Premium12.99x
Gearing15.83x
Moneyness 0.9374
Difference Strike 31.29 $
Difference Strike %+6.26%
Spread 0.06 €
Spread %2.15%
Theoretical value 2.730
Implied Volatility 28.25 %
Total Loss Probability 61.43 %
Intrinsic value 0.000000
Present value 2.730
Break even 529.29 €
Theta-0.09x
Vega0.12x
Rho0.09x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
468.7 USD
Average target price
463.4 USD
Spread / Average Target
-1.13%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant